Karina Melissa Soto-Ruiz

Karina Melissa Soto-Ruiz

Auto-generated profile, based on publicly available information

Karina Melissa Soto-Ruiz

Comprehensive Research Associates

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2019 in JMIR Aging
Verified
Journal Article
Open access
SGSamantha Groppell
Samantha Groppell
KSKarina M Soto-Ruiz
Karina M Soto-Ruiz
BFBenjamin Flores
Benjamin Flores
WDWilliam Dawkins
William Dawkins
ISIsabella Smith
Isabella Smith
YKYael Katz
Yael Katz
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: The U.S. population over the age of 65 is expected to double by the year 2050. Concordantly, the incidence of dementia is projected to increase. The subclinical stage of dementia begins years before signs and symptoms appear. Early detection of cognitive impairment and/or cognitive decline may allow for interventions to slow its progression. Furthermore, early detection may allow for implementation of care plans that may affect the quality of life of those affected and their caregivers Objective: We sought to determine the accuracy and validity of BrainCheck Memory as a diagnostic aid for age-related cognitive impairment, as compared against other commonly used neurocognitive screening tests -the SLUMS test, the MMSE, and the MoCA - and against physician diagnosis. Methods: We tested 583 volunteers over the age of 49 from various community centers and living facilities in Houston, TX. The volunteers were divided into five cohorts: a normative population, and four comparison groups for SLUMS, MMSE, MoCA, and physician diagnosis. Each comparison group completed their respective assessment and BrainCheck Memory. Results: 398 subjects were included in the normative population. 84 participants were in the SLUMS cohort, 51 in the MMSE cohort, 35 in the MoCA cohort, and 18 in the physician cohort. BrainCheck Memory assessments were significantly correlated to the SLUMS, with coefficients ranging from 0.5 to 0.7. Correlation coefficients for the MMSE and BrainCheck and the MoCA and BrainCheck were also significant. Of the 18 subjects evaluated by a physician, nine were healthy, six were moderately impaired, and three were severely impaired. A significant difference was found between the severely/moderately impaired and the healthy (p=.02). We derived a BrainCheck Memory composite score that showed stronger correlations with the standard assessments as compared to the individual BrainCheck assessments. ROC curve analysis of this composite score found a sensitivity of 81% and a specificity of 94%. Conclusions: BrainCheck Memory provides a sensitive and specific metric for age-related cognitive impairment in older adults, with the advantages of a mobile, digital, and easy-to-use test. Clinical Trial: Video Games to Track Cognitive Health. Clinical Trials.gov identifier: NCT03608722. https://clinicaltrials.gov/ct2/show/NCT03608722?term=braincheck&rank=1

6 September 2024 in Clinical and Experimental Emergency Medicine
Verified
Journal Article
Open access
PDF file
WPWilliam Peacock
William Peacock
KSKarina Melissa Soto-Ruiz
Karina Melissa Soto-Ruiz
AJAllan Jaffe
Allan Jaffe
BTBrian R. Tiffany
Brian R. Tiffany
SMSimon A. Mahler
Simon A. Mahler
RCRobert H. Christenson
Robert H. Christenson
Objective: Chest pain, a common emergency department presentation, requires rapid evaluation. The current gold standard of care is serial troponin measurements from blood draws along with an electrocardiogram and clinical presentation. However, an optical technology-based noninvasive wearable device, the Infrasensor, which can rapidly and transcutaneously assesses cardiac troponin I (cTnI), was recently developed. We aimed to perform a pilot study to evaluate the performance of the Infrasensor in cTnI defined cohorts.Methods: This was a 10-hospital prospective observational study in healthy US subjects with a normal cTnI level and in patients with an elevated local cTnI level. Healthy subjects as determined by a negative questionnaire and bloodwork underwent 3-minute Infrasensor measurement and levels of high-sensitivity cTnI (hs-cTnI), n-terminal pro-B-type natriuretic peptide (NTproBNP), creatinine, and glycosylated hemoglobin (HbA1c) were evaluated from blood. Patients with elevated cTnI had the same Infrasensor and blood sample measurements. Using a fivefold cross-validation technique, cTnI-based binary classification models that did and did not include age were trained on 80% and validated on 20% of the dataset (n=168; elevated hs-cTnI equally partitioned into five nearly equally-sized subsets ). Results: Of 840 patients, 727 (87.5%) had normal (nonelevated) cTnI levels while the remaining 113 had elevated cTnI. Median age was 61 years (interquartile range, 52–71 years) for the elevated cohort and 48 years (interquartile range, 32–57 years) for the nonelevated. Overall, 416 (50.5%) were female, with 33 of 113 (29.2%) in the elevated cohort and 383 of 727 (52.7%) in the nonelevated cohort. Overall, the sensitivity, specificity, negative and positive predictive values of the Infrasensor for identifying elevated cTnI were 0.90, 0.70, 0.98 and 0.48, respectively, with a C-statistic of 0.90 (95% confidence interval, 0.89–0.99).Conclusion: The Infrasensor accurately identifies elevated cTnI within 3 minutes of application.

26 October 2018 in JMIR Preprints
Verified
Preprint
Open access
SGSamantha Groppell
Samantha Groppell
KSKarina M Soto-Ruiz
Karina M Soto-Ruiz
BFBenjamin Flores
Benjamin Flores
WDWilliam Dawkins
William Dawkins
ISIsabella Smith
Isabella Smith
YKYael Katz
Yael Katz
BACKGROUND The US population over the age of 65 is expected to double by the year 2050. Concordantly, the incidence of dementia is projected to increase. The subclinical stage of dementia begins years before signs and symptoms appear. Early detection of cognitive impairment and/or cognitive decline may allow for interventions to slow its progression. Furthermore, early detection may allow for implementation of care plans that may affect the quality of life of those affected and their caregivers. OBJECTIVE We sought to determine the accuracy and validity of BrainCheck Memory as a diagnostic aid for age-related cognitive impairment, as compared against physician diagnosis and other commonly used neurocognitive screening tests, including the Saint Louis University Mental Status (SLUMS) exam, the Mini-Mental State Examination (MMSE), and the Montreal Cognitive Assessment (MoCA). METHODS We tested 583 volunteers over the age of 49 from various community centers and living facilities in Houston, Texas. The volunteers were divided into five cohorts: a normative population and four comparison groups for the SLUMS exam, the MMSE, the MoCA, and physician diagnosis. Each comparison group completed their respective assessment and BrainCheck Memory. RESULTS A total of 398 subjects were included in the normative population. A total of 84 participants were in the SLUMS exam cohort, 51 in the MMSE cohort, 35 in the MoCA cohort, and 18 in the physician cohort. BrainCheck Memory assessments were significantly correlated to the SLUMS exam, with coefficients ranging from .5 to .7. Correlation coefficients for the MMSE and BrainCheck and the MoCA and BrainCheck were also significant. Of the 18 subjects evaluated by a physician, 9 (50%) were healthy, 6 (33%) were moderately impaired, and 3 (17%) were severely impaired. A significant difference was found between the severely and moderately impaired subjects and the healthy subjects (P=.02). We derived a BrainCheck Memory composite score that showed stronger correlations with the standard assessments as compared to the individual BrainCheck assessments. Receiver operating characteristic (ROC) curve analysis of this composite score found a sensitivity of 81% and a specificity of 94%. CONCLUSIONS BrainCheck Memory provides a sensitive and specific metric for age-related cognitive impairment in older adults, with the advantages of a mobile, digital, and easy-to-use test. CLINICALTRIAL ClinicalTrials.gov NCT03608722; https://clinicaltrials.gov/ct2/show/NCT03608722 (Archived by WebCite at http://www.webcitation.org/76JLoYUGf)

16 January 2026 in medRxiv
Verified
Preprint
Open access
PDF file
JTJitto Titus
Jitto Titus
JKJessie Katz
Jessie Katz
KSKarina Soto-Ruiz
Karina Soto-Ruiz
RCRobert H. Christenson
Robert H. Christenson
AWAlan Hb Wu
Alan Hb Wu
WPWilliam Frank Peacock
William Frank Peacock
Object: Transdermal biosensors may provide an alternative to conventional blood-based biomarker measurement. Our purpose was to determine the binary correlation between transdermal (Infrasensor; RCE, Inc, Carlsbad, CA) and conventional blood-based measurements. Methods: This was a secondary analysis from a previously published observational cardiac troponin I (cTnI) study performed to establish the upper reference level of cTnI, at 10 US hospitals. After obtaining informed consent, 2 cohorts of patients were enrolled: 1) those who completed a health assessment questionnaire and appeared healthy, and 2) those with a known elevated cTnI per the local hospital standard assay. All blood lab analyses were performed at the University of Maryland Medical Center, Baltimore, MD. Normal was defined as cTnI <53.48 ng/L (male) or 34.11 ng/L (female) using the Siemens Atellica IM assay (Siemens Medical Solutions, Mountain View, CA), NT-proBNP 75 years) or <124 pg/mL (1.17 mg/dL (male) or >0.95 mg/dL (female), and HbA1c <6.4%. The Infrasensor was placed on the patient's wrist for measurement and blood drawn for analysis at approximately the same time. Results: Of 840 enrolled patients, the median (IQR) age was 46 (30,57), 416 (49.5%) were female, 10.36% Hispanic, 6.7% Asian, 12.9% African American, and 69.1% White. Elevated lab tests were 102 hscTnI's, 156 NTproBNP's, 37 HbA1C's, and 163 creatinine's. Significant binary correlations were found between all transdermal signals and the corresponding lab blood levels Conclusion: Infrasensor transcutaneous measurement demonstrates similar results as that obtained from blood testing in the central laboratory.

1 January 2012
Verified
Book Chapter
Closed access
PDF file
KSKarina M. Soto-Ruiz
Karina M. Soto-Ruiz
JVJoseph Varon
Joseph Varon
WPW. Frank Peacock
W. Frank Peacock